224 related articles for article (PubMed ID: 36116682)
21. Therapeutic targets for bone metastases in breast cancer.
Clézardin P
Breast Cancer Res; 2011 Apr; 13(2):207. PubMed ID: 21586099
[TBL] [Abstract][Full Text] [Related]
22. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer.
Bonneau C; Eliès A; Kieffer Y; Bourachot B; Ladoire S; Pelon F; Hequet D; Guinebretière JM; Blanchet C; Vincent-Salomon A; Rouzier R; Mechta-Grigoriou F
Breast Cancer Res; 2020 Jul; 22(1):76. PubMed ID: 32665033
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer.
Brechbuhl HM; Xie M; Kopin EG; Han AL; Vinod-Paul K; Hagen J; Edgerton S; Owens P; Sams S; Elias A; Sartorius CA; Tan AC; Kabos P
Mol Carcinog; 2022 Mar; 61(3):359-371. PubMed ID: 34856027
[TBL] [Abstract][Full Text] [Related]
24. State of art and advances on the treatment of bone metastases from breast cancer: a concise review.
Rossi L; Longhitano C; Kola F; Del Grande M
Chin Clin Oncol; 2020 Apr; 9(2):18. PubMed ID: 32036675
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss.
Murali B; Ren Q; Luo X; Faget DV; Wang C; Johnson RM; Gruosso T; Flanagan KC; Fu Y; Leahy K; Alspach E; Su X; Ross MH; Burnette B; Weilbaecher KN; Park M; Mbalaviele G; Monahan JB; Stewart SA
Cancer Res; 2018 Oct; 78(19):5618-5630. PubMed ID: 30093561
[TBL] [Abstract][Full Text] [Related]
26. Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.
Park SH; Keller ET; Shiozawa Y
Calcif Tissue Int; 2018 Feb; 102(2):152-162. PubMed ID: 29094177
[TBL] [Abstract][Full Text] [Related]
27. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
28. Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer.
D'Oronzo S; Silvestris E; Paradiso A; Cives M; Tucci M
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32344743
[TBL] [Abstract][Full Text] [Related]
29. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment.
Kang J; Choi YJ; Seo BY; Jo U; Park SI; Kim YH; Park KH
Sci Rep; 2019 Jun; 9(1):8726. PubMed ID: 31217507
[TBL] [Abstract][Full Text] [Related]
30. Bone Metastasis of Breast Cancer.
Tahara RK; Brewer TM; Theriault RL; Ueno NT
Adv Exp Med Biol; 2019; 1152():105-129. PubMed ID: 31456182
[TBL] [Abstract][Full Text] [Related]
31. Role of bone-anabolic agents in the treatment of breast cancer bone metastases.
Suvannasankha A; Chirgwin JM
Breast Cancer Res; 2014; 16(6):484. PubMed ID: 25757219
[TBL] [Abstract][Full Text] [Related]
32. RANK pathway in cancer: underlying resistance and therapeutic approaches.
Tufail M; Wu C
J Chemother; 2023 Sep; 35(5):369-382. PubMed ID: 36200617
[TBL] [Abstract][Full Text] [Related]
33. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
34. Chemokines in bone-metastatic breast cancer: Therapeutic opportunities.
Wang Y; Ren S; Wang Z; Wang Z; Zhu N; Cai D; Ye Z; Ruan J
Int Immunopharmacol; 2020 Oct; 87():106815. PubMed ID: 32711376
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
[TBL] [Abstract][Full Text] [Related]
36. Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer.
O'Shaughnessy J; Campone M; Brain E; Neven P; Hayes D; Bondarenko I; Griffin TW; Martin J; De Porre P; Kheoh T; Yu MK; Peng W; Johnston S
Ann Oncol; 2016 Jan; 27(1):106-13. PubMed ID: 26504153
[TBL] [Abstract][Full Text] [Related]
37. Reactive oxygen species (ROS): Critical roles in breast tumor microenvironment.
Malla R; Surepalli N; Farran B; Malhotra SV; Nagaraju GP
Crit Rev Oncol Hematol; 2021 Apr; 160():103285. PubMed ID: 33716202
[TBL] [Abstract][Full Text] [Related]
38. Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells.
Wang W; Belosay A; Yang X; Hartman JA; Song H; Iwaniec UT; Turner RT; Churchwell MI; Doerge DR; Helferich WG
Clin Exp Metastasis; 2016 Jun; 33(5):475-85. PubMed ID: 27209469
[TBL] [Abstract][Full Text] [Related]
39. Immune parameters associated with survival in metaplastic breast cancer.
Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
[TBL] [Abstract][Full Text] [Related]
40. Recent developments in treatment stratification for metastatic breast cancer.
Barton S; Swanton C
Drugs; 2011 Nov; 71(16):2099-113. PubMed ID: 22035512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
